|
Monday 8th December 2025 |
Text too small? |
Rua Bioscience is pleased to provide an update on the progress of its pro rata rights offer currently open to eligible shareholders.
To date the Company has received commitments for over $1.5 million from existing shareholders, with a total of $2 million on offer. This demonstrates strong support for Rua’s strategy and the objectives of the capital raise. These commitments reflect the confidence of shareholders in the Company’s commercial progress, operational execution, and long-term growth ambitions in the global medicinal cannabis sector.
The pro rata rights offer remains open until the end of day on Friday, 12 December 2025. Any shareholder that wishes to participate should do so before this date. Full details of the offer, including the timetable and instructions on how to take up rights, are set out in the Offer Document available at www.ruabio.com/capital-raise-november-2025.
Funds raised through the Rights Offer will be applied to working capital and marketing activities to support Rua’s growth opportunities, including the launch and commercialisation of new products across key international markets such as Germany, Australia, the United Kingdom, and Czechia.
ENDS
No comments yet
KMD completes Placement and Institutional Entitlement Offer
SML - North Island asset sale completed
RAD - Radius Care Expansion Continues with Care Home Acquisition
PFI - Property for Industry Limited Bond Offer Final Terms Sheet
April 1st Morning Report
FSF - Fonterra completes sale of Mainland Group to Lactalis
GNE - Resignation of Chief Financial Officer
PFI - Property for Industry Limited Launches Bond Offer
March 30th Morning Report
HGH Ltd Results for the 6 months ended 1 February 2026